Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells

Leukemia Research

Volumn 34, Issue 10, 2010, Pages 1351-1357

  Litzinger, Mary T ^a   Foon, Kenneth A ^b,c   Tsang, Kwong Yok ^a   Schlom, Jeffrey ^a   Palena, Claudia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

CD40L; CLL; Immunotherapy; TRICOM; Vaccine

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD40 LIGAND; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; VIRUS VECTOR;

ARTICLE; CANCER IMMUNIZATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EX VIVO GENE TRANSFER; GENETIC IMMUNIZATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEUKEMIA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANTIGENS, CD58; ANTIGENS, CD80; CANCER VACCINES; CD40 LIGAND; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; VACCINIA VIRUS;

EID: 77955980318     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.12.013     Document Type: Article

References (37)

1. Wierda W.G., Kipps T.J. Chronic lymphocytic leukemia. Curr Opin Hematol 1999, 6:253-261.
2. Tsimberidou A.M., Keating M.J. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009, 115:2824-2836.
3. Pleyer L., Egle A., Hartmann T.N., Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009, 6:405-418. [Epub June 2, 2009].
4. Buhmann R., Nolte A., Westhaus D., Emmerich B., Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999, 93:1992-2002.
5. Rezvany M.R., Jeddi-Tehrani M., Rabbani H., Lewin N., Avila-Carino J., Osterborg A., et al. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. Br J Haematol 2000, 111:608-617.
6. Ranheim E.A., Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993, 177:925-935.
7. Van den Hove L.E., Van Gool S.W., Vandenberghe P., Bakkus M., Thielemans K., Boogaerts M.A., et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997, 11:572-580.
8. Kato K., Cantwell M.J., Sharma S., Kipps T.J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998, 101:1133-1141.
9. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000, 96:2917-2924.
10. Takahashi S., Rousseau R.F., Yotnda P., Mei Z., Dotti G., Rill D., et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther 2001, 12:659-670.
11. Biagi E., Dotti G., Yvon E., Lee E., Pule M., Vigouroux S., et al. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood 2005, 105:2436-2442. [Epub November 9, 2004].
12. Hodge J.W., Grosenbach D.W., Rad A.N., Giuliano M., Sabzevari H., Schlom J. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 2001, 19:3552-3567.
13. Palena C., Zhu M., Schlom J., Tsang K.Y. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood 2004, 104:192-199. [Epub March 9, 2004].
14. Briones J., Timmerman J.M., Panicalli D.L., Levy R. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst 2003, 95:548-555.
15. Palena C., Foon K.A., Panicali D., Yafal A.G., Chinsangaram J., Hodge J.W., et al. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood 2005, 106:3515-3523.
16. Gritz L., Destree A., Cormier N., Day E., Stallard V., Caiazzo T., et al. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol 1990, 64:5948-5957.
17. Chahroudi A., Garber D.A., Reeves P., Liu L., Kalman D., Feinberg M.B. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 2006, 80:8469-8481.
18. Greiner S., Humrich J.Y., Thuman P., Sauter B., Schuler G., Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol 2006, 146:344-353.
19. Wendtner C.M., Kofler D.M., Mayr C., Bund D., Hallek M. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors. Leuk Lymphoma 2004, 45:897-904.
20. Cantwell M.J., Sharma S., Friedmann T., Kipps T.J. Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood 1996, 88:4676-4683.
21. Blanchard T.J., Alcami A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998, 79:1159-1167.
22. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998, 79:347-352.
23. Mayr A., Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 1978, 41:225-234.
24. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003, 22:21-29.
25. Harrer E., Bauerle M., Ferstl B., Chaplin P., Petzold B., Mateo L., et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 2005, 10:285-300.
26. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12:1032-1040.
27. Carroll M.W., Overwijk W.W., Chamberlain R.S., Rosenberg S.A., Moss B., Restifo N.P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 1997, 15:387-394.
28. Belyakov I.M., Wyatt L.S., Ahlers J.D., Earl P., Pendleton C.D., Kelsall B.L., et al. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol 1998, 72:8264-8272.
29. Ramirez J.C., Gherardi M.M., Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000, 74:923-933.
30. Oie K.L., Pickup D.J. Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappaB activation. Virology 2001, 288:175-187.
31. Guerra S., Lopez-Fernandez L.A., Conde R., Pascual-Montano A., Harshman K., Esteban M. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 2004, 78:5820-5834.
32. Hodge J.W., Higgins J., Schlom J. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. Vaccine 2009, 27:4475-4482. [Epub May 29, 2009].
33. Ledbetter J.A., Shu G., Gallagher M., Clark E.A. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40). J Immunol 1987, 138:788-794.
34. Crawford D.H., Catovsky D. In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology 1993, 80:40-44.
35. Romano M.F., Lamberti A., Tassone P., Alfinito F., Costantini S., Chiurazzi F., et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998, 92:990-995.
36. Kitada S., Zapata J.M., Andreeff M., Reed J.C. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999, 106:995-1004.
37. Kater A.P., Evers L.M., Remmerswaal E.B., Jaspers A., Oosterwijk M.F., van Lier R.A., et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004, 127:404-415.